 Zynerba Pharmaceuticals Inc NASDAQ:ZYNE has boosted its international intellectual property IP portfolio, revealing it has been granted a new US patent for its cannabidiol-formulated gel Zygel. The US patent and trademark office issued the patent, which is entitled Treatment of Fragile X Syndrome With Cannabidiol, and includes claims directed to methods of treating Fragile X syndrome with cannabidiol, the company said in a statement. 